RecruitingPhase 1NCT06953934

A Mass Balance Study of Oral [14C] ABBV-932 in Healthy Adult Male Participants

Mass Balance Study of [14C] ABBV-932 Following Single Oral Dose Administration in Healthy Male Volunteers

Sponsor

AbbVie

Enrollment

8 participants

Start Date

May 4, 2026

Study Type

INTERVENTIONAL

Conditions

The main objective of this study is to assess the safety and tolerability of ABBV-932 in healthy adult male participants.

Sex: MALEMin Age: 18 YearsMax Age: 65 Years

Body Mass Index (BMI) ≥ 18.0 to ≤ 29.9.0 kg/m\^2 after rounding to the tenths decimal. BMI is calculated as weight in kg divided by the square of height measured in meters.
Male participant who is not considering fathering a child or donating sperm during the study and for 100 days after the study drug administration
A condition of general good health, based upon the results of a medical history, physical exam

Has not participated in another \[14C\] absorption, distribution, metabolism, excretion (ADME) study with a radiodose above 0.1 MBq in the period of 12 months prior to screening.
Use of any medications/products known to alter drug absorption, metabolism, or excretion processes, within 30 days or within a period defined by 5 half-lives, whichever is longer, prior to study drug administration.
Prior exposure to ABBV-932 or cariprazine within the past 90 days.

Interested in this trial?

Get notified about updates and connect with the research team.